GT Biopharma (GTBP)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	6.51 mm	6.51 mm	6.51 mm	6.51 mm	6.51 mm	6.51 mm
Cash burn (monthly)	912.67 k	(no burn)	1.20 mm	1.15 mm	912.33 k	572.08 k
Cash used (since last report)	2.57 mm	n/a	3.38 mm	3.24 mm	2.57 mm	1.61 mm
Cash remaining	3.94 mm	n/a	3.13 mm	3.27 mm	3.94 mm	4.90 mm
Runway (months of cash)	4.3	n/a	2.6	2.8	4.3	8.6

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2023

GTBP institutional ownership history Ownership history

7.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	2	34	-94.1%
Opened positions	1	5	-80.0%
Closed positions	33	7	+371.4%
Increased positions	0	7	EXIT
Reduced positions	0	8	EXIT

13F shares	Current	Prev Q	Change
Total value	1.67 mm	2.51 bn	-99.9%
Total shares	3.02 mm	5.08 mm	-40.6%
Total puts	0.00	1.00 k	EXIT
Total calls	0.00	6.50 k	EXIT
Total put/call ratio	–	0.2	–

Largest owners	Shares	Value	Change
Cytovance Biologics	2.76 mm	$860.00 k	NEW
Alpha Capital Anstalt	265.23 k	$809.00 k	0.0%

Largest transactions	Shares	Bought/sold	Change
Cytovance Biologics	2.76 mm	+2.76 mm	NEW
Armistice Capital	0.00	-2.20 mm	EXIT
Vanguard	0.00	-1.13 mm	EXIT
BLK BlackRock	0.00	-375.06 k	EXIT
Geode Capital Management	0.00	-223.44 k	EXIT
Baskin Financial Services	0.00	-151.35 k	EXIT
WFC Wells Fargo & Company	0.00	-100.56 k	EXIT
BK The Bank of New York Mellon Corporation	0.00	-95.24 k	EXIT
STT State Street	0.00	-81.88 k	EXIT
Renaissance Technologies	0.00	-69.40 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

GTBP insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
17 Oct 24	Urban Alan Louis	Option to purchase Common Stock Common Stock	Grant	Acquire A	No	No	2.11	23,335	49.24 k	23,335
11 Aug 23	Manu Ohri	Common Stock	Other	Acquire J	Yes	No	0.287	200,000	57.40 k	300,000
11 Aug 23	Manu Ohri	Common Stock	Other	Dispose J	No	No	0.287	200,000	57.40 k	0
11 Aug 23	Manu Ohri	Common Stock	Grant	Acquire A	No	No	0.287	200,000	57.40 k	200,000
11 Aug 23	Michael Martin Breen	Common Stock	Grant	Acquire A	No	No	0.287	200,000	57.40 k	856,218

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

12 Health Care Stocks Moving In Monday's Pre-Market Session

23 Dec 24

Roth MKM Initiates Coverage On GT Biopharma with Buy Rating, Announces Price Target of $11

2 Dec 24

Roth MKM analyst Jonathan Aschoff initiates coverage on GT Biopharma (NASDAQ:GTBP) with a Buy rating and announces Price Target of $11.

GT Biopharma Q3 EPS $(1.53) Up From $(1.77) YoY

14 Nov 24

GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(1.53) per share. This is a 13.56 percent increase over losses of $(1.77) per share from the same period last year.

Press releases

From Benzinga Pro

GT Biopharma Reports Third Quarter 2024 Financial Results

14 Nov 24

GTB-3650 TriKE® Phase 1 trial first patient dosed expected in Q4 2024; initial clinical data expected in Q2 2025GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors expected in 1H

GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

26 Sep 24

SAN FRANCISCO, CALIFORNIA, Sept. 26, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the